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Abstract
Objective: Transcranial magnetic stimulation (TMS) produces characteristic
deflections in the EEG signal named TMS-evoked EEG potentials (TEPs), which
can be used to assess drug effects on cortical excitability. TMS can also be used to
determine the resting motor threshold (RMT) for eliciting a minimal muscle
response, as a biomarker of corticospinal excitability. XEN1101 is a novel potas-
sium channel opener undergoing clinical development for treatment of epilepsy.
We used TEPs and RMT to measure the effects of XEN1101 in the human brain,
to provide evidence that XEN1101 alters cortical excitability at doses that might be
used in future clinical trials. Methods: TMS measurements were incorporated in
this Phase I clinical trial to evaluate the extent to which XEN1101 modulates
TMS parameters of cortical and corticospinal excitability. TEPs and RMT were
collected before and at 2-, 4-, and 6-hours post drug intake in a double-blind,
placebo-controlled, randomized, two-period crossover study of 20 healthy male
volunteers. Results: Consistent with previous TMS investigations of antiepilep-
tic drugs (AEDs) targeting ion channels, the amplitude of TEPs occurring at
early (15–55 msec after TMS) and at late (150–250 msec after TMS) latencies
were significantly suppressed from baseline by 20 mg of XEN1101. Further-
more, the RMT showed a significant time-dependent increase that correlated
with the XEN1101 plasma concentration. Interpretation: Changes from baseline
in TMS measures provided evidence that 20 mg of XEN1101 suppressed corti-
cal and corticospinal excitability, consistent with the effects of other AEDs.
These results support the implementation of TMS as a tool to inform early-
stage clinical trials.
Introduction
Epilepsy is a very common disorder in which approxi-
mately one third of patients do not respond to available
antiepileptic drugs (AEDs).1 There is therefore a
continued need to develop more efficacious AEDs. One of
the crucial challenges for early-stage development of new
AEDs is to assess whether the investigational compound
can cross the blood brain barrier (BBB) and whether it is
acting at the intended target. Positron emission
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
1
tomography (PET) or collection of cerebrospinal fluid
can provide evidence, however, they are invasive, expen-
sive, and not easily accessible. Potentially, electro-diagnos-
tic markers (EDM) could provide an efficient and reliable
way to demonstrate the cortical activity of AEDs.
Transcranial magnetic stimulation (TMS) is a non-in-
vasive brain stimulation technique.2 Responses resulting
from motor cortex stimulation can be measured peripher-
ally with electromyographic (EMG) recording over con-
tralateral muscles or more directly via
electroencephalography (EEG). Multiple AEDs and other
drugs acting in the brain have shown effects on TMS-
EMG3 and TMS-EEG4 measures. The TMS-EEG response
shows alternating positive and negative peaks at charac-
teristic latencies, called TMS-evoked EEG potentials
(TEPs).5 TEPs represent the summation of TMS-induced
excitatory and inhibitory neuronal processes.6 Although
the complete physiological mechanism underlying TEPs is
still unresolved, a growing body of evidence indicates that
TMS-EDM can reliably detect drug-induced changes in
cortical excitability. Thus, TMS-EDM has significant
potential to serve as a reliable and efficient biomarker to
demonstrate in early-stage clinical trials that a drug can
cross the BBB and engage its relevant target.
Here, we provide proof-of-principle for this approach
in a phase I clinical trial of XEN1101, an AED in early
stage clinical development. XEN1101 is a novel potassium
channel opener with the same mechanism of action as
retigabine. We hypothesized that XEN1101 would show
TMS-EDM effects, modulating cortical excitability consis-
tent with previous TMS studies of AEDs.7–9 As predicted,
we found that XEN1101 had strong effects on RMT and
TEPs, which suggests that it reduces cortical excitability.
This study provides evidence for the feasibility and utility
of TMS for the assessment of AED target engagement and
pharmacodynamic effects early during drug development.
Method
Drug information
XEN1101 is a novel positive allosteric modulator (“opener”)
of the potassium channel KCNQ2/3 (Kv7.2/7.3) currently
being developed by Xenon Pharmaceuticals Inc. for the
treatment of focal epilepsy. Potentiating the open state of
KCNQ2/3 channels favors a hyperpolarized resting state.10
This mechanism has been clinically proven effective for focal
onset seizures using the KCNQ2/3 opener, retigabine.11–13
Phase I clinical study
The experimental protocol was approved by the MHRA,
local ethics committees, and all participants gave written
informed consent (ClinicalTrials.gov Identifier:
NCT03468725).
The study investigated the safety, tolerability, and phar-
macodynamic profile of single doses of XEN1101 (20 mg)
in 20 healthy male subjects using a randomized, double-
blind, placebo-controlled, two-period crossover design.
All subjects were right-handed (Edinburgh Handedness
Inventory laterality score ≥ 75%).14 Participants remained
under supervision until discharge on Day 2. Following a
6-day washout, subjects returned to the unit on Day 7 to
receive the alternate treatment and remained under super-
vision until discharge on Day 8. Subjects returned on Day
14 for a follow-up and completed a telephone interview
on Day 37 (Fig. 1A).
In treatment periods, safety assessments including vital
signs, physical examination, electrocardiograms, clinical labo-
ratory evaluations, and Columbia-Suicide Severity Rating
Scale scores were obtained predose and at selected postdose
time points. Pharmacokinetics (PK) were assessed with blood
samples collected on Day 1 and 7 (predose) and at selected
postdose time points on Days 1-2 and 7-8. Pharmacodynamic
(PD) assessments, including TMS-EMG and TMS-EEG mea-
surements, were conducted on Day 1 and 7 at predose and at
2- and 4-hours post dose (Fig. 1B). After blinded review of
the PK profiles indicated slow absorption, additional TMS-
EMG and TMS-EEG assessments were added at 6 hours post-
dose in the remaining 16 and 8 subjects, respectively.
Data acquisition
TMS-EMG
We used a Magstim 2002 stimulator connected to a fig-
ure-of-eight coil (diameter 90 mm) through a BiStim
(Magstim Co). Single TMS pulses were applied over the
hand area of left motor cortex (M1) to elicit motor
evoked potentials (MEPs) in the right first digital inter-
osseous (FDI) muscle, recorded using surface EMG
(20 Hz to 2 kHz; D360 amplifier, Digitimer, Hertford-
shire, UK). Resting motor threshold (RMT), active motor
threshold (AMT), and short-interval intracortical inhibi-
tion (SICI) were measured. RMT was determined using
the relative frequency method.15,16 AMT was recorded
while subjects squeezed a manometer at 20% of maxi-
mum contraction. SICI was measured using stimuli pairs
at interstimulus interval of 2 msec, with 15 conditioning
stimulus at 80% AMT and 15 test stimulus 120% RMT.17
The position of the FDI hotspot was marked with a felt
tip pen on the EEG cap to ensure constant coil placement
throughout an experimental session. Furthermore, coil
position and orientation relative to the marked position
were carefully monitored by the experimenter throughout
stimulation and corrected if necessary (i.e., if the
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participant moved). Importantly, the double-blind design
ensured that no systematic error could be introduced.
TMS-EEG
Subjects were seated with eyes open while fixating. During
stimulation subjects listened to a colored masking noise18
whose intensity was adjusted individually in each experi-
mental session, until the participant reported that they were
unable to hear the TMS-click. TMS-compatible EEG equip-
ment (BrainAmp MRplus, BrainProducts GmbH) with a
64-electrode cap (Multitrodes, BrainCap-Fast’n Easy) was
used. 150 consecutive TMS stimuli, with inter-trial interval
of approximately 4 sec (random variation of 20%), were
applied at 100% RMT. RMT was obtained before and at 2,
4, and 6 h after drug administration. In each TMS-EEG ses-
sion the stimulation intensity was kept relative to the pre-
drug RMT. PK blood samples were obtained ~5 min before
each postdose TMS measurement period.
Data analysis and statistics
TMS-EMG
EMG data were analyzed via Spike2 software (Cambridge
Electronic Design). Peak-to-peak MEP amplitudes were
measured for each trial and averaged per condition. SICI
was calculated as the ratio of mean conditioned MEP to
mean unconditioned MEP.
Drug-induced changes in RMT, AMT, and SICI were
evaluated using a two-way rmANOVA (Bonferroni cor-
rected) with a within subject design and a main effect of
Time [four levels for RMT and AMT (pre, 2-, 4-, and 6-h
postdrug intake) and three levels for SICI (pre, 2- and 4-
h postdrug intake)] and Drug (two levels: active and pla-
cebo). Missing values were replaced by the average per
experimental condition.
TMS-EEG
The analysis of TMS-EEG data was performed offline,
blinded to drug conditions, using Brain Vision Analyzer,
Fieldtrip (version 2016, http://www.fieldtriptoolbox.org)
and custom scripts in Matlab 2012b version 7.7 (Math-
Works, Natick, Mass).7
After excluding trials with prominent eye movements,
blinks, and muscle artifacts, EEG data were down-sam-
pled to 1 kHz, segmented into epochs from 1 sec before
and after the TMS pulse. A linear interpolation
for  10 msec was applied to remove the TMS artifact.
An average of 3 (1–5 range) bad channels were removed
Figure 1. (A) CONSORT diagram of the randomized, double-blind, placebo-controlled, two-period crossover study from screening to the follow-up call.
(B) TMS-EMG assessments (RMT, AMT, and SICI) and TMS-EEG procedures undertaken during Day 1 and Day 7. After placing the EEG cap and after
localization of left M1 best stimulation target area (hotspot) TMS-EMG and TMS-EEG were obtained for each participant and experimental session,
before and 2, 4, and 6 h after drug intake. The blood sample was obtained ~5 min before the postdose TMS measurements.
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from the EEG, and the signal was reconstructed by inter-
polating the surrounding electrode signals. Data were
notch filtered (50 Hz) and residual artifacts related to the
TMS pulse (e.g., TMS recharging artifact, muscle decay
artifact), eye-blinks, saccades, and muscle movement were
removed by Independent Component Analysis (ICA). On
average, 17 components (range 4–24) were deleted follow-
ing the procedures described in a previous report.19
Finally, remaining data were baseline-corrected (from
600 to 50 msec), band-pass filtered (2–80 Hz) and re-
referenced to the average channel signal.
TEPs were calculated by averaging artifact-free EEG tri-
als for each drug condition. To smooth the signal a low-
pass filter of 45 Hz was applied to TEPs. The average
number of trials for each condition is reported in Table 1.
We studied the following TEP components (value in
parenthesis denotes the time of interest, TOI): N15-P25
(15–35 msec), N45 (35–70 msec), P70 (70–80 msec),
N100 (80–145 msec), and P180 (145–230 msec). TOIs
were chosen on the basis of the grand-averaged TEPs and
kept identical across all analyses. To analyse drug-induced
modulation of TEPs, we selected a region of interest
(ROI) that was composed of 27 channels around the
stimulation site and the corresponding contralateral site
(FC1, FC3, FC5, C1, C3, C5, CP1, CP3, CP5, P1, P3, P5,
Cz, CPz, Pz, FC2, FC4, FC6, C2, C4, C6, CP2, CP4, CP6,
P2, P4, P6). We analyzed TEP components at four time
points (predose, 2, 4, and 6 h post dose, where available)
in each of the two sessions (placebo, active drug) in each
individual.
To investigate the impact of XEN1101 on TEPs, we
applied multiple paired t-tests (post vs. predrug intake)
on the level of individual electrodes within ROI, within
each drug condition and each TOI separately. A nonpara-
metric, cluster-based permutation analysis as imple-
mented in Fieldtrip was used to control for multiple
comparisons across channels and time points within
TOIs.20 Clusters were defined as adjacent time point-
channel pairs for which the t-statistic exceeded a thresh-
old of P < 0.05. Cluster-level statistics were calculated
based on the sum of t-values within each cluster. Monte
Carlo P-values were computed based on 1500 random
permutations and a value of P < 0.05 was used as the
cluster-statistical significance threshold for all compar-
isons.
We applied Spearman correlation analyses to investi-
gate significant correlation between drug-induced modu-
lation (post minus predrug) of TMS-EMG/EEG measures
and peak plasma concentration of XEN1101.
Finally, to exclude the possibility that changes in TEPs
are explained by drug induced changes in RMT reflected
by amplitude of MEPs, the change in the percentage of
suprathreshold MEPs (>0.5 mV) between pre and post-
conditions was calculated and used as a covariate in a
post hoc multivariate ANOVA with within-subjects fac-
tors CONDITION (predrug, postdrug), and TEP-PEAK
(each significant TEP effect).
Results
Subjects (n = 20) had a mean age  standard deviation
(SD) of 26.6  5.9 years (range 19–40 years), and a
mean weight  SD of 72.3  9.5 kg. They all partici-
pated in all requisite study visits and there were no
dropouts. One subject did not receive any of the TMS
measurements at the 2 h time point in the XEN1101
treatment period due to an adverse event (vomiting).
TMS-EEG procedures could not be completed for
another subject at 2 h in the placebo treatment period
due to technical problems, so at 2 h this subject only
underwent RMT.
XEN1101 safety, tolerability, and
pharmacokinetics
The drug was overall safe and well tolerated. AEs occur-
ring in two or more subjects during XEN1101 treatment
included dizziness, somnolence, fatigue, disturbance in
attention, and headache (Table 2). Compared to placebo,
the only related AE reaching a statistically significant dif-
ference (P < 0.05) in terms of incidence was dizziness.
There were no deaths, SAEs, or withdrawals due to AEs.
There were no clinically significant changes in clinical lab-
oratory evaluations, vital signs, or ECG.
The mean  SD of maximum plasma concentration
(Cmax) of XEN1101 was 59.2  13.8 ng/mL (N = 20). The
median time to peak plasma concentration (Tmax) was 7.8 h
(range 1.9 12 h). The time to peak was slightly earlier in
Period 1 compared to Period 2, however, the median
XEN1101 Tmax occured after the TMS measurement time
points in both periods. At the TMS assessment time points
of 2, 4, and 6 h postdose, mean (SD) XEN1101 plasma
concentrations were 15.7  21.5 ng/mL, 30.2  21.9 ng/
mL, and 42.1  19.1 ng/mL, respectively (Fig. 2).
Table 1. Number of artefact free EEG trials.
Number of Artefact Free EEG Trials (Mean, Range)
Pre dose 2 h Post 4 h Post 6 h Post
Placebo 128
(90, 142)
121
(98, 136)
125
(105,137)
125
(101,137)
XEN1101 130
(106,149)
124
(102,145)
123
(94,139)
131
(110,141)
Average number and range of artefact free TMS-EEG trials before and
after placebo and XEN1101 intake.
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Due to the slow drug elimination, participants who
received XEN1101 in Period 1 had small carry-over drug
levels in their placebo arm (highest XEN1101 concentra-
tion at start of second period: 8.2 ng/mL). In addition,
four participants did not reach XEN1101 concentrations
higher than the carry-over observed in the placebo arm
(8.2 ng/mL).
Given the PK profile, XEN1101-induced modulation of
TMS measurements was evaluated as an effect of concen-
tration (using the postdose measure taken during highest
drug exposure vs. baseline) and of time (comparisons of
2, 4, and 6 h postdose vs. predose). To remove the poten-
tial carry-over effect, analyses were performed for selected
participants (n = 16) who showed drug plasma levels
higher than the highest concentration detected as a carry-
over in the placebo arm.
Effects of XEN1101 on TMS-EMG measures
The repeated-measure ANOVA for RMT showed a signifi-
cant effect of Drug (F1,15 = 7.3; P = 0.009), Time
(F1.3,20 = 8.1; P = 0.006) and a significant interaction
between Drug and Time (F3,45 = 9.7; P < 0.001). The
interaction was explained by a significant time-dependent
increase in RMT at 4 h (P = 0.001) and 6 h (P = 0.001)
after XEN1101 intake. There were no significant effects
for placebo over time (P > 0.05). Finally, compared to
placebo the RMT was significantly higher for XEN1101 at
4 h (P = 0.009) and at 6 h (P < 0.001) (Fig. 3A).
The repeated-measure ANOVA for AMT showed a signif-
icant Drug by Time interaction (F1.7, 26 = 6.4, P = 0.007).
Compared to predrug state the AMT was significantly
increased at 4 h (P = 0.001) and at 6 h (P = 0.04). In the
comparison with placebo, AMT was significantly higher at
4 h (P = 0.03) and at 6 h (P = 0.001) (Fig. 3B).
XEN1101 did not show significant modulation of SICI
(P > 0.05). At the time of individual highest XEN1101
concentration, during the RMT assessments (i.e., at 2, 4,
or 6 h), there was a significant positive correlation
between changes in RMT and Xen plasma concentration
(r = 0.5; P = 0.02; Fig. 3C). Other correlations were not
significant (P > 0.05).
Effects of XEN1101 on TEPs
The spatiotemporal profile of the TMS-evoked EEG
potentials is in line with previous reports21 (Fig. 4A and
4). The comparison between predrug conditions (pre-
placebo versus pre-XEN1101) did not show significant
differences (P > 0.05).
Concentration analysis
During TMS measurement sessions with highest concen-
tration in each individual, compared to baseline,
XEN1101 decreased the amplitude of the early TEPs com-
ponents measured from 15 to 25 msec over the stimu-
lated left motor area (N15-P25, P = 0.005), and at
45 msec (N45, P = 0.007) and 180 msec (P180, P = 0.02)
over contralateral sites (Fig. 5A). Compared to time-
matched placebo, XEN1101 decreased the N45 potential
in the contralateral hemisphere (P = 0.002), and the P180
amplitude (P = 0.02) over fronto-central sites (Fig. 5B).
Drug-induced changes in TEPs did not correlate with
XEN1101 peak plasma levels (P > 0.05).
Time analysis
The cluster-based permutation analysis was applied
between postdose and predose conditions to test the
effects of XEN1101 at 2 h (n = 15), 4 h (n = 16), and
6 h (n = 7) after dosing in subjects with adequate
XEN1101 exposure during the first 6 h. Compared to pre-
dose, the first N15-P25 complex was decreased at 2 h
(P = 0.008) and 4 h (P = 0.02). Furthermore, at 4 h after
dosing XEN1101 significantly suppressed the N45
(P = 0.03), the N100 (P = 0.04), and the P180
(P = 0.004) (Fig. 6). Other comparisons were not statisti-
cally significant (P > 0.05).
Table 2. List of adverse events.
System organ class preferred term
Overall
XEN1101 20 mg
(N = 20)
Placebo
(N = 20)
n (%) E n (%) E
Any Related1 AE 19 (95.0) 65 7 (35.0) 10
Nervous system disorders 17 (85.0) 48 7 (35.0) 8
Dizziness 10 (50.0) 12 1 (5.0) 1
Somnolence 8 (40.0) 11 5 (25.0) 5
Headache 3 (15.0) 6 0
Disturbance in attention 5 (25.0) 5 1 (5.0) 1
Tension headache 4 (20.0) 4 1 (5.0) 1
Ataxia 2 (10.0) 2 0
Diplopia 2 (10.0) 2 0
Vision blurred 2 (10.0) 2 0
General disorders and
administration site conditions
7 (35.0) 7 1 (5.0) 1
Fatigue 6 (30.0) 6 1 (5.0) 1
Gastrointestinal disorders 2 (10.0) 3 0
Nausea 2 (10.0) 2 0
Cardiac disorders 2 (10.0) 2 0
Sinus tachycardia 2 (10.0) 2 0
% - (n/N)*100, N for overall column is the total number of subjects in
both periods who received XEN1101 20 mg or placebo.
N, Number of subjects having a treatment emergent adverse event;
N, Number of subjects at risk; E, Number of events.
1Related AE: possibly related or definitely related AE.
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Interaction between TEPs and EMG
recording
Average MEP amplitudes and the change in the percent-
age of suprathreshold MEPs (>0.5 mV) between pre and
postdrug measurements are calculated and are shown in
Table 3. The repeated measures ANOVA showed that
there is no interaction between CONDITION and change
in the percentage of suprathreshold MEPs, and no three-
way interaction between CONDITION, TEP-PEAK (N15-
P25, N45, and P180) and change in the percentage of
suprathreshold MEPs (all P > 0.05).
Discussion
TMS measurements were incorporated in a healthy volun-
teer Phase I clinical trial to provide indirect evidence that
the investigational drug crosses the BBB and early
Figure 2. XEN1101 plasma concentrations (ng/mL) are reported as a function of time (hour) for Day 1 (blue line) and Day 7 (green line).
XEN1101 shows a profile characterized by a prolonged absorption and XEN1101 was detectable (<8.22 ng/mL) during the placebo period at the
second visit (Day7; blue line from 168 to 192 h). TMS assessments, indicated by the black TMS figure-of-eight coil, were performed prior to dose
and in the ascending part of the absorption curves at 2 h (15.7  21.5) ng/mL, 4 (h 30.2  21.1 ng/mL), and 6 h (44.4  20.2 ng/mL).
Figure 3. RMT (panel A) and AMT (panel B) mean values  SEM (%MSO) are reported for each time point (Pre, 2 h, 4 h, and 6 h post drug
intake) for XEN1101 (red line) and placebo (blue line). Black lines with P values indicate significant effects with respect to baseline. Panel C shows
the significant positive correlation between RMT changes (postdrug minus predrug observed at the maximum systemic exposure) and XEN1101
plasma levels (ng/mL).
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Figure 4. Spatiotemporal profile of TEPs after Placebo and XEN1101 administration. Panel A shows grand-average (n = 16) butterfly plots before
(Pre; blue) and after (Post; red) intake of placebo (left) and XEN1101 (right). Each line represents TEPs recorded at a single EEG channel.
Topographical scalp distributions of the amplitude (µV) of the main TEP components (N15-P25, N45, N100, and P180) before and after drug
intake are shown in panel B and C respectively. Panel D represents t-statistic maps of the TEP amplitude showing postdrug versus pre-drug
differences. Nonsignificant results are indicated by n.s. and black asterisks indicate channels that showed a significant drug-induced modulation.
Figure 5. XEN1101 modulation of TEP amplitude at highest concentration compared to pre intake (A) and to time-matched placebo (B). TEPs
grand-averaged over channels which showed significant drug-induced effects, indicated by asterisks in the topography plots of t-values. These are
TEP data averaged over 16 participants with postdose conditions selected at highest drug exposure during TMS evaluation. Compared to pre-dose
(A, blue) and placebo (B, blue), XEN1101 (red) induced a suppression of the N15-P25, N45, and P180 components.
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readouts of pharmacodynamic effects. XEN1101 showed
significant plasma concentration dependent reduction of
corticospinal and cortical excitability, as measured with
RMT and TEPs, respectively. The modulation of TMS-
EDM is consistent with AEDs with similar modes of
action and these results support further development of
XEN1101 as an AED.
The effects of XEN1101 on TMS-EMG
measures
Following administration of XEN1101, we observed that
the RMT was increased in a time- and plasma concentra-
tion-dependent manner in comparison to baseline and
placebo. These results provide evidence for XEN1101’s
ability to reduce cortical excitability with a strong PK/PD
relationship.
RMT and AMT are typically increased by several AEDs
blocking sodium channels, such as lamotrigine7,22 and car-
bamazepine,23 or opening potassium channels9 (i.e., retiga-
bine). Opening KV7.2/7.3 potassium channels plays a crucial
role in suppressing neuronal excitability as this shifts the
membrane potential toward a more hyperpolarized state.
The effects of XEN1101 on TMS-EEG
measures
Administration of XEN1101 produced statistically signifi-
cant modulations of TEPs consistent with effects of other
AEDs.7,8 At the time of the highest plasma levels during
TMS assessments XEN1101 decreased the amplitudes of
the N15-P25 complex, the N45, and the P180 potentials.
In addition, drug-induced TEP modulation correlated
with drug plasma exposure with strong effects at 4 h after
drug intake.
The N15 component is generated in the ipsilateral pre-
motor cortex. The origin of P25 is less clear, but it may
reflect activity around ipsilateral motor cortex, ipsilateral
cingulate gyrus or supplementary motor area, and in the
contralateral cortex.24 In a study of patients with progres-
sive myoclonic epilepsy, the P25 waveform was increased,
suggesting an association with elevated cortical excitabil-
ity.25 The N15-P25 complex has been correlated with
MEP amplitude, thus providing information about the
excitability of the stimulated area.24 Following this inter-
pretation and similar to findings with carbamazepine, the
reduction of the peak-to-peak amplitude of these early
components may reflect the drug-induced reduction of
cortical excitability.8 In addition, this study is accumulat-
ing evidence for another footprint of AED activity, which
is the late TMS component (P180). Prior studies have
suggested that the P180 may be a residual of the auditory
evoked signal.26,27 However, given that we applied a
masking noise that minimizes the AE,18,28 and the prior
evidence that drugs like carbamazepine do not modulate
the amplitude of the auditory evoked response,29 we
believe that the XEN1101 effects on the P180 reflect a
modulation of the TMS-evoked brain responses. Finally,
Figure 6. XEN1101 modulation of TEPs amplitude at 2, 4, and 6 h after dosing. Mean amplitude values  SEM recorded at the level of
significant channels before, 2 h (n = 15), 4 h (n = 16), and 6 h (n = 7) after XEN1101 intake. XEN1101 fingerprints which include the reduction
in the N15-P25, N45, and P180 components reflect increasing plasma exposure over time.
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XEN1101 suppressed the N45 amplitude which has been
linked to GABA-A receptor mediated neurotransmission
by studies that manipulated TEPs with benzodiazepines as
GABAergic positive modulators.30,31 The N45 reduction
could reflect less inhibition, speculatively due to decreased
GABA release into the synaptic cleft after hyperpolariza-
tion of the presynaptic terminal. Alternatively, the TMS
response may not have propagated to contralateral sites
given the overall increase in cortical inhibition, which
may have reduced the N45 amplitude over distant sites.
However, the N45 modulation sits in contrast to the
increase produced by lamotrigine and levetiracetam over
channels ipsilateral to the stimulated site. This specific
action has been speculated to be related to indirect
activity of the two AEDs at the level of GABA-A
receptors.32–34
Implications and limitations
This study provides compelling evidence that TMS can
play a valuable role in providing pharmacodynamic mea-
sures of target engagement in early stage trials. Further-
more, a systemically administered drug, such as
XEN1101, with central PD effects, such as modulation of
TMS outputs, indirectly indicates that the drug crosses
the BBB. The introduction of TMS-EDM in early trials
may help avoid excessive exposure of volunteers to high
and toxic dosages, thereby limiting AEs, may contribute
valuable information about the dose range to be tested in
later-stage trials, and strongly supports the advancement
of the new therapeutic into phase 2 clinical development.
In addition, the intrinsic neuronal membrane properties
and level of cortical excitation and inhibition are relevant
mechanisms in epileptogenesis.35 Therefore, from a clini-
cal perspective, TMS endpoints may play a valuable role
when determining the therapeutic effects of XEN1101 in
epilepsy patients.
When considering that TMS-EEG is approaching clini-
cal translation,4,36 it must be taken into account that the
TMS pulse can induce unwanted somatosensory responses
that have an impact on the cortical signal detected with
EEG.37 An online TEP quality control during data collec-
tion will be crucial to obtain high-quality and genuine
TMS-evoked brain responses. Furthermore, if protocol
allows it, blocks of adjusted and unadjusted stimulation
intensity should be assessed under a TMS navigated set-
ting. This would help to understand whether TEP changes
reflect an effect of the drug on the generators of TEPs,
rather than just reflecting the consequences of a reduction
of corticospinal excitability and relative change in RMT.
In addition, it must be noted that given the novel drug
pharmacokinetic profile, in some participants TMS mea-
sures were not performed at the highest drug exposure.Ta
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Therefore, our results may be an underestimate of the
true pharmacological effect. Furthermore, in some sub-
jects dosed with active drug at the first session, there was
measurable XEN1101 in the plasma a week later at the
placebo session, although there was no difference in base-
line between periods.
In conclusion, this study showed that TMS can provide
a landscape of early electro-diagnostic readouts to help
shape future development of new therapeutics. In addi-
tion to epilepsy, this approach could be applied in the
context of a variety of neurological and neuropsychiatric
conditions.
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